Voyager Therapeutics, Inc. (NASDAQ:VYGR – Get Free Report) insider Sandell Jacquelyn Fahey sold 5,999 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total value of $34,914.18. Following the completion of the sale, the insider now owns 86,001 shares in the company, valued at approximately $500,525.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Voyager Therapeutics Stock Performance
Shares of NASDAQ:VYGR traded up $0.17 during midday trading on Thursday, reaching $5.99. 567,458 shares of the company’s stock traded hands, compared to its average volume of 637,196. The company has a market cap of $325.82 million, a P/E ratio of -116.40 and a beta of 0.91. The company has a fifty day simple moving average of $6.82 and a two-hundred day simple moving average of $7.91. Voyager Therapeutics, Inc. has a 1 year low of $5.71 and a 1 year high of $11.72.
Voyager Therapeutics (NASDAQ:VYGR – Get Free Report) last announced its earnings results on Tuesday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.20. Voyager Therapeutics had a net margin of 6.28% and a return on equity of 3.31%. The business had revenue of $29.58 million for the quarter, compared to analyst estimates of $11.52 million. During the same quarter last year, the business earned ($0.51) earnings per share. As a group, research analysts forecast that Voyager Therapeutics, Inc. will post -1.44 EPS for the current fiscal year.
Institutional Investors Weigh In On Voyager Therapeutics
Analysts Set New Price Targets
VYGR has been the topic of several recent research reports. HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a research report on Tuesday, August 20th. Wedbush dropped their price target on shares of Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 7th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $17.83.
Get Our Latest Research Report on VYGR
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.
Featured Stories
- Five stocks we like better than Voyager Therapeutics
- Investing in Construction Stocks
- When Is the Best Time to Invest in Mutual Funds?
- Insider Trades May Not Tell You What You Think
- Is NVIDIA Stock in a Correction or Consolidation?
- What is the Dogs of the Dow Strategy? Overview and Examples
- 3 Oversold Stocks with Big RSI Rebound Potential
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.